Bristol-Myers Squibb Co (BMY) Shares Bought by Northwestern Mutual Wealth Management Co.

Share on StockTwits

Northwestern Mutual Wealth Management Co. raised its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 123,418 shares of the biopharmaceutical company’s stock after acquiring an additional 2,323 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Bristol-Myers Squibb were worth $6,830,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Raymond James Financial Services Advisors Inc. boosted its position in shares of Bristol-Myers Squibb by 2.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock worth $22,827,000 after purchasing an additional 10,456 shares in the last quarter. Integrated Investment Consultants LLC boosted its position in shares of Bristol-Myers Squibb by 1,748.8% during the 2nd quarter. Integrated Investment Consultants LLC now owns 63,468 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 60,035 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Bristol-Myers Squibb by 2.8% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 43,171 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 1,161 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of Bristol-Myers Squibb by 19.1% during the 2nd quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock worth $58,813,000 after purchasing an additional 170,360 shares in the last quarter. Finally, Formidable Asset Management LLC boosted its position in shares of Bristol-Myers Squibb by 7.7% during the 2nd quarter. Formidable Asset Management LLC now owns 13,901 shares of the biopharmaceutical company’s stock worth $769,000 after purchasing an additional 998 shares in the last quarter. 72.29% of the stock is currently owned by institutional investors and hedge funds.

NYSE:BMY opened at $60.48 on Wednesday. The company has a quick ratio of 1.28, a current ratio of 1.40 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $98.97 billion, a price-to-earnings ratio of 20.09, a PEG ratio of 1.53 and a beta of 1.02. Bristol-Myers Squibb Co has a 52 week low of $49.96 and a 52 week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The firm had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter last year, the business posted $0.74 EPS. equities analysts forecast that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current year.

BMY has been the topic of a number of research analyst reports. Atlantic Securities raised shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 price objective on the stock in a research report on Wednesday, August 8th. SunTrust Banks restated a “buy” rating and issued a $67.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, July 31st. Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Sunday, July 15th. UBS Group lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 target price on the stock. in a report on Monday, May 21st. Finally, BMO Capital Markets upped their target price on shares of Bristol-Myers Squibb from $47.00 to $51.00 and gave the stock a “market perform” rating in a report on Monday, July 23rd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $63.11.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: Earnings Per Share

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply